Immunovant, Inc. (IMVT)
NEUTRAL基本面
31
价格
$43.47
市值
$9.01B
第一部分 · 这家公司值多少
概览
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
0
截至2026/3/31的财政年度
净利润
$-506M
截至2026/3/31的财政年度
自由现金流
$-407M
股东权益合计
$853M
负债合计
$104M
流动比率
7.27
利息覆盖率
-
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$48.88
当前价格
$43.47
安全边际
+11.1%
公允价值区间
$46.43 - $51.32
估算方法
估值指标
市盈率（P/E）
-
ROE
-59.3%
市净率（P/B）
12.17
P/FCF
-
毛利率
-
ROIC
-
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
-
WACC
9.1%
ROIC − WACC
-
基本面分析标准
通过（5）
- Price CAGR 15.82%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 82% Buy
未通过（9）
- EPS shows upward trend
- P/B Ratio 12.17
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -69.6%
- Earnings Surprise avg -5.5%
- Share Dilution 20.4%
- Piotroski F-Score 2/9
不可用（13）
- ROIC NaN%
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-评分
存在严重财务隐患
盈利质量
低质量：需深入审查会计处理
股权稀释
正在发行新股，稀释所有权
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board | 46 |
| Dr. Eric Venker M.D., Pharm.D. | CEO & Director | 38 |
| Mr. Tiago M. Girao CPA | Chief Financial Officer | 46 |
| Ms. Melanie Gloria B.S.N. | Chief Operating Officer | 47 |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer | 62 |
| Mr. Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Christine Blodgett | Senior Vice President of Human Resources | - |
| Ms. Becky Merlina | Senior VP & Global Head of Quality | - |
| Ms. Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming & Data Management | - |
| Ms. Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development | - |
审计风险
4
董事会风险
10
薪酬风险
9
股东权利风险
10
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for IMVT, sourced from Markets Gazette.
- 3/15/2026POSITIVEA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
A healthcare hedge fund has significantly increased its stake in Immunovant Inc., acquiring an additional $24.5 million worth of stock. Immunovant is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases. Its lead candidate is currently undergoing Phase II trials. This substantial investment by a specialized healthcare fund suggests strong conviction in the company's pipeline and future prospects. For investors, this move could signal positive upcoming developments or a favorable risk-reward profile for Immunovant's stock.
- 3/11/2026POSITIVEImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Inc. (IMVT) experienced a significant surge, with its stock price climbing 30%. This upward momentum comes despite a notable insider trimming their stake by $3 million. The company, which focuses on antibody therapies for autoimmune diseases, has seen its lead candidate advance through clinical trials. This progress in its drug development pipeline is a key driver for investor optimism, suggesting potential future revenue streams and market expansion. The stock's performance indicates strong market confidence in Immunovant's therapeutic pipeline and its long-term growth prospects, outweighing the impact of the insider's partial divestment.
via Markets Gazette